Idaho Technology Receives FDA 510(k) Clearance for Expanded FilmArray Respiratory Panel
25 May 2012

Technology, Inc., a privately held clinical diagnostics company providing high-quality instruments for pathogen identification and DNA analysis, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of five additional pathogens for its FilmArray® Respiratory Panel (FilmArray RP), a user-friendly Multiplex pathogen detection system. FilmArray RP is now FDA-cleared for 20 viral and bacterial respiratory pathogens.

“We are pleased to offer a more robust and simpler way to test for upper respiratory tract infections,” said Kirk Ririe, Chief Executive Officer of Idaho Technology. “Gaining clearance of these additional pathogens for FilmArray RP is an accomplishment long-anticipated by our users in the hospital clinical laboratory community because it improves laboratory testing capacity while providing the fastest way to better results.”

With the addition of these five pathogens, the FilmArray RP now includes the first FDA cleared assays for 8 of the 20 organisms on the panel. Furthermore, the FilmArray RP is the only FDA-cleared panel capable of distinguishing between certain bacterial and viral respiratory infections. This represents a significant advancement in the field of infectious disease detection, with the potential to provide clinical laboratories and physicians with more comprehensive, actionable information to guide treatment decisions and improve patient outcomes.

The additional five pathogens are; Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Coronavirus 229E, and Coronavirus OC43. Bordetella pertussis outbreaks in recent months have highlighted
the need for an FDA-cleared test that can rapidly and accurately distinguish viral infections from more serious bacterial illness.

Mr. Ririe Continued, “Our expanded respiratory panel highlights the diagnostic potential of our dynamic and innovative FilmArray platform. After almost one year on the market with FilmArray RP, we have been very encouraged by the market acceptance we’ve received. We expect, based on current demand for our product and our growing pipeline of additional clinical diagnostic tests, to establish a leadership position in clinical diagnostics, building upon our legacy and expertise in pathogen identification.”

Idaho Technology is currently developing additional applications for their FilmArray system including a blood culture ID panel, gastrointestinal pathogens panel, and an STD panel. The Company expects to begin clinical testing its blood culture ID panel later this year.

Request Info


Company website

Biofire Diagnostics
profile photo

Sonia Nicholas
Clinical Diagnostics Editor